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Abstract
Precision medicine (PM) is increasingly recognized as the way forward for optimizing
patient care. Introduced in the field of oncology, it is now considered of major inter-
est in other medical domains like allergy and chronic airway diseases, which face an
urgent need to improve the level of disease control, enhance patient satisfaction
and increase effectiveness of preventive interventions. The combination of personal-
ized care, prediction of treatment success, prevention of disease and patient partici-
pation in the elaboration of the treatment plan is expected to substantially improve
the therapeutic approach for individuals suffering from chronic disabling conditions.
Given the emerging data on the impact of patient stratification on treatment out-
comes, European and American regulatory bodies support the principles of PM and
its potential advantage over current treatment strategies. The aim of the current
document was to propose a consensus on the position and gradual implementation
of the principles of PM within existing adult treatment algorithms for allergic rhinitis
(AR) and chronic rhinosinusitis (CRS). At the time of diagnosis, prediction of success
of the initiated treatment and patient participation in the decision of the treatment
plan can be implemented. The second-level approach ideally involves strategies to
prevent progression of disease, in addition to prediction of success of therapy, and
patient participation in the long-term therapeutic strategy. Endotype-driven treat-
ment is part of a personalized approach and should be positioned at the tertiary
level of care, given the efforts needed for its implementation and the high cost of
molecular diagnosis and biological treatment.
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1 | INTRODUCTION
A new paradigm to advance medical care is precision medicine
(PM).1 The four Ps of PM stand for personalized, predictive, preven-
tive and participatory. PM encourages a convergence of omics, sys-
tems medicine, innovative health information technology and
consumer-driven health care. Global multidiscipline partnerships and
the right balance between research and policy priorities are needed
to achieve the audacious goal of PM. Applying the principles of PM
at the point of care is one of the major challenges for development
of the future healthcare system.
Precision medicine is a medical model aiming at the customiza-
tion of health care—with medical decisions, practices and/or prod-
ucts tailored to the individual patient.2 Based on the knowledge of
mechanisms of the disease, PM generally combines diagnosis and
treatment to select optimal management.3,4
The concept of PM is not new. Clinicians have always observed
that patients with similar symptoms may have different diseases,
with different causes, and that treatment may have different out-
comes depending on a multitude of individual external and endoge-
nous factors. The novelty comes from the rapid technological
advances, including omics, medical imaging, regenerative medicine,
biobanks and registries, along with an increased computational
power and innovative health information technology (HIT). This will
allow real-time clinical decision support at the point of care with
implementation of harmonized care based on quality criteria and
patients to be treated and monitored more precisely and effectively
to better meet their individual needs.2 In addition, other providers
will play a larger role in routine care for less complex cases and dur-
ing follow-up.
Precision medicine is rapidly gaining more attention in molecular
diagnosis-based treatment of cancer5 and other diseases. The practi-
cal implementation of PM is however more difficult in complex dis-
eases such as multimorbid chronic diseases.3,6 Nonetheless, one
recent example of successful application was reported in cystic fibro-
sis. In 4% of the patients, the specific intervention based on the
molecular mechanism can totally reverse the disorder.7 In allergic dis-
eases, PM principles have always been used, in particular for patients
receiving allergen immunotherapy (AIT).8 AIT is tailored to the
patient’s sensitization profile and it has a long-lasting and preventive
effect.9 Despite major advances in understanding allergic diseases,
many patients with upper airway diseases are still uncontrolled10,11
and primary prevention is still unknown. Recently, a PRACTALL
report highlighted the need for PM in airway diseases.12
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Chronic upper airway inflammation can be roughly divided into
two major clinical entities, that is rhinitis and rhinosinusitis. The aller-
gic phenotype is the best characterized phenotype of rhinitis from a
pathophysiologic point of view.13 The diagnosis of allergic rhinitis
(AR) requires the proof of IgE-mediated hypersensitivity using appro-
priate skin or blood tests and the implication of the relevant allergen
in eliciting the symptoms.14 Allergic and nonallergic rhinitis often
coexist, but the treatment response differs,15 and many patients only
use “over-the-counter” (OTC) medications.16 Chronic rhinosinusitis
(CRS) is classically divided into a phenotype with and without endo-
scopic or radiologic evidence of nasal polyps (CRSwNP and CRSsNP,
respectively).17
Both AR and CRS are characterized by inflammation and are
divided into the mild, moderate and severe subgroups, and for both,
anti-inflammatory medication represents the first-line treat-
ment.13,17,18 The use of nasal endoscopy and CT imaging may not
be sufficient to fully appreciate the individual patients’ pathology.
Endotyping of CRS on the basis of physiological, functional and
pathological characteristics might provide information on the risk of
disease progression or recurrence and on the best available treat-
ments, and also helps in identifying innovative therapeutic targets
for treatment.19
The Allergic Rhinitis and its Impact on Asthma (ARIA) treatment
algorithms provide evidence-based guidelines for treatment of
AR.13,20 Multiple treatment options, strategies and approaches can
be applied depending on the level of control achieved or aiming for.
In AR, AIT is recommended when pharmacotherapy is not successful,
or as an alternative to long-term pharmacotherapy. Surgical reduc-
tion of the inferior turbinate(s) or correction of a septal deviation
might be indicated when nasal obstruction persists as a major symp-
tom in adequately medically treated AR patients. The European Posi-
tion Paper on Rhinosinusitis and Nasal Polyps (EPOS) treatment
algorithms provide evidence-based guidelines for treatment of
CRS.17 Anti-inflammatory medication in combination with saline
douching represents the first step of treatment for CRS, with adap-
tation of the therapeutic regimen dependent on the degree of con-
trol.17 Surgery is considered if prolonged medical treatment fails, but
up to 40% of patients remain symptomatic despite sinus surgery.21
Medical treatment for any condition aims at controlling the
disease including clinically significant symptom reduction with
improvement of quality of life and reduction of socio-economic
impact of the disorder. In contrast to other diseases like asthma22
and despite the high prevalence of AR and CRS,23,24 the con-
cept of control of disease has only recently been introduced in
AR10,25 and CRS.17 However, this concept is important to define
those patients with difficult-to-treat disease, representing a diag-
nostic and therapeutic challenge and having a large socio-eco-
nomic burden.26,27 After defining those patients with uncontrolled
disease, factors associated with lack of control can be identified,
and better insights can be obtained in global airway disease con-
trol.28 Recently, uncontrolled disease in AR and CRS has been
reported to reach 35% and 40% of patients treated in academic
referral centres respectively, underscoring the need for novel and
better strategies of care for both AR and CRS.21,29 Nowadays, it
is clear that there is a need to optimize treatment and embrace
the principles of PM in chronic airways diseases in order to
achieve a higher level of control of disease.
This review is an initiative taken by the nonprofit EUFOREA
leadership in conjunction with ARIA, EPOS and AIRWAYS
ICPs 16,17,30 (European Innovation Partnership on Active and Healthy
Ageing, Action Group B3) experts who felt the need to provide a
comprehensive overview of the current state of the art on control in
upper airway diseases, with a focus on the different factors involved
in uncontrolled upper airway inflammation as well as the unmet
needs in this domain. In addition, a proposal for gradual implementa-
tion of the principles of PM into the adult management algorithms
of AR and CRS is made.
2 | GRADUAL IMPLEMENTATION OF THE
FOUR PRINCIPLES OF PRECISION MEDICINE
IN ALLERGIC RHINITIS
2.1 | First-level management of AR
Allergic Rhinitis is diagnosed based on the combination of a history
of two or more nasal symptoms, nasal examination showing inflam-
matory changes in untreated patients and confirmation of the suspi-
cion of sensitization by skin prick tests or specific IgE tests.
At the time of the first diagnosis of AR in medical or specialist
office, a therapeutic plan is elaborated taking into account the major
presenting symptoms, the severity and impact of symptoms, comor-
bidities and availability of treatment (Figure 1).
At present, it seems clear that two key principles of PM can
easily be implemented at the time of elaboration of a therapeutic
plan (Figure 2):
• Prediction of success of treatment: The treatment strategy may be
guided using a recent algorithm proposed by worldwide
experts.31 Physicians treating patients with AR should be aware
of the different therapeutic strategies for AR and adapt to the
patients’ profile (MACVIA-ARIA), preferences and needs, taking
into account the availability and accessibility to the recom-
mended treatment choice. Up to 50% of patients treated for AR
want to be informed about the different treatment options and
strategy applied at the time of diagnosis.32 Therefore, the following
information on prediction of success of treatment on nasal, ocular,
bronchial and general symptoms should be communicated to AR
patients:
○ Information on the expected onset of action and benefit of
treatment of different treatment options, both on symptom
severity and on general functioning and quality of life
○ Information on the shortcomings, safety and potential adverse
events of different treatment options and approaches
○ Information on the impact of treatment of AR on the comor-
bidities, like asthma, otitis media and eczema
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• Participation of the patient: Given the proven efficacy of several
active compounds for AR, the different routes of administration
of treatment and the different aims of treatment, patients can be
empowered to become an active partner in the elaboration of the
following strategic choices for first-line treatment for AR (after
receiving and understanding the above info):
○ Choice of oral versus nasal route of administration of effec-
tive molecules
○ Choice of combined treatment versus monotherapy
○ Choice of corticosteroidal versus noncorticosteroidal treat-
ment options
○ Choice of pharmacological treatment versus allergen-specific
immunotherapy
Patient education is crucial in this process to allow patients to
assess and self-monitor symptom severity and control, to properly
use medication and to be informed about whom to seek for medical
advice.
After having elaborated a treatment strategy with the AR
patient, it is recommended to evaluate the degree of symptom
control regularly using mobile technology or after a time interval
of 2-4 weeks by physician’s visits. Symptom control in AR can be
evaluated via different means, but a visual analogue scale (VAS)
score seems to be a good tool for control evaluation in real clini-
cal life.29,33,34 Telemonitoring enables convenient evaluation of
patients on a regular basis. Clinical Decision Support Systems
(CDSS), interactive computer software, is designed to assist health
professionals with decision-making tasks, such as determining
F IGURE 2 Precision medicine
implementation in allergic rhinitis. Qol,
quality of life; AIT, allergen immunotherapy
F IGURE 1 Graded implementation of
precision medicine in allergic rhinitis
(adapted from Hellings et al. 11). VAS,
visual analogue scale; TNS, total nasal
symptoms; IT, immunotherapy; AR, allergic
rhinitis
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treatment strategies of patient using the results of ICPs. MASK
(MACVIA-ARIA sentinel network for rhinitis) includes all these fea-
tures.31,35,36
2.2 | Second-level management of AR
Following the initiation of first-line treatment, uncontrolled patients
are invited for evaluation of symptom control and fine-tuning of the
treatment strategy accordingly. Besides taking into account the
achieved level of control by first-line treatment, a treatment strategy
is elaborated according to the revised needs and expectations of the
patient, the experienced efficacy and/or adverse events of the medi-
cation used, the availability of medication and the long-term goal of
maintaining or achieving disease control and prevent disease pro-
gression.
Therefore, the following three key principles of PM can be imple-
mented during the follow-up consultation for AR (Figure 2):
• Prediction of success of any step-down or step-up approach, based
on the input from the patient on the expected benefits
• Participation of the patient in the management plan
• Prevention of disease progression with clear statements on the dif-
ferent approaches for suppression of inflammation vs prevention
of disease progression:
○ Secondary prevention aims at preventing the acquisition of
new sensitizations and the onset of asthma in those AR
patients who have not developed asthma yet. Evidence-based
therapeutic interventions for the secondary prevention of
asthma fall into three categories:
■ Pharmacological treatment
■ Allergen-specific immunotherapy37
■ Control of environmental allergens and cigarette smoke
○ Tertiary prevention aims at preventing irreversible damage to
the inflamed organ, maximizing the remaining capabilities and
functions of the organ.
2.3 | Third-level management of AR
Following second-line treatment, uncontrolled patients are invited
to attend outpatient clinics for evaluation and advise regarding
long-term therapeutic strategy. At this stage, the majority of
AR patients with uncontrolled disease are seeking specialist advice.
At specialist level, a treatment plan should ideally be
proposed according to the needs of the patient, the achieved level
of control, the availability of medication and the long-term
ambition.
All four key principles of PM should be implemented during the
follow-up consultation for AR at specialist level (Figure 2):
• Prediction of success of any step-down or step-up approach, with
information on the expected benefits and risks of adverse events
of long-term treatment
• Participation of the patient in the therapeutic plan, with clear
information on the goals and practical implications of different
therapeutic strategies in the short and long term
• Prevention of disease progression with clear statements on the dif-
ferent approaches for suppression of inflammation versus strate-
gies for secondary (and tertiary) prevention of asthma. In
occupational rhinitis, measures to prevent chronicity and develop-
ment of asthma should be recommended, despite the major impact
of the implementation. In AR, the sensitization pattern should guide
the strategy for prevention of asthma, including the option of AIT.
• Personalized care with a treatment plan proposed on the base of
the major or most bothersome symptom(s), the comorbidities, the
endotype (type 2 inflammation, mixed inflammation or neurogenic
inflammation and barrier impairment) and the patients’ prefer-
ences, should be envisaged
2.4 | Integrated care pathways (ICPs)
A large number of AR patients do not consult physicians because
they think AR symptoms are normal and/or trivial whereas AR
impacts social life, school and work productivity.13 Many AR patients
use OTC drugs16 and only a fraction have a medical consultation.
The vast majority of patients visiting GPs or specialists have moder-
ate/severe rhinitis.38-42 Integrated care pathways differ from practice
guidelines as they are utilized by a multidisciplinary team and have a
focus on the quality and coordination of care, thus corresponding
ideally to the requests of PM implementation at the point of care.43
An ICP is intended to act as a guide to holistic disease management
in a stepwise and feedback manner. AIRWAYS ICPs have proposed a
multisectoral care pathway for AR (Figure 3 from35).
3 | GRADUAL IMPLEMENTATION OF THE
FOUR PRINCIPLES OF PRECISION MEDICINE
IN CRS
3.1 | First-level management of CRS
Chronic rhinosinusitis diagnosis is based on the presence of two or
more sino-nasal symptoms and either CT scan for nonotorhinolaryn-
gologists, supplemented by allergy tests in case of suspicion of con-
comitant allergy, and/or nasal endoscopy by otorhinolaryngologists
for phenotyping into CRS with and without nasal polyps (CRSwNP
and CRSsNP).
At the time of the first diagnosis of CRS in general or specialist
practice, a therapeutic plan is elaborated taking into account the
major presenting symptoms, the severity and impact of symptoms
and comorbidities like asthma or chronic obstructive pulmonary dis-
ease (COPD) (Figure 4).44,45 First-line treatment can be considered
by every clinician taking care of patients with CRS.
At present, it seems clear that the following two key parameters
of PM can easily be implemented at the time of elaboration of a first
therapeutic plan (Figure 5):
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• Prediction of success of treatment: Physicians treating patients
with CRS should be aware of the different therapeutic modalities
for CRS, involving nasal steroids, nasal douching, avoidance of
exposure to cigarette smoke and (professional) irritants and treat-
ment of allergy in case of relevant sensitization and adapt to
patient profile (EPOS), preferences and needs, taking into
account the availability and accessibility to the recommended
treatment choice. Therefore, the following information on predic-
tion of success of treatment should be communicated to CRS
patients:
○ Information on the expected onset of action and benefit of
treatment of different treatment options, both on the symp-
tom severity and on general functioning and quality of life
○ Information on the shortcomings, safety and potential adverse
events of different treatment options and approaches
○ Information on the impact of treatment of CRS on the comor-
bidities, like asthma or COPD
○ Impact of exposure to irritants and allergens
• Participation of the patient: Given the proven efficacy of different
options for treatment of CRS, patients are empowered as active
partners in the elaboration of the following strategic choices for
first-line treatment for CRS:
○ Choice of combined nasal corticosteroid treatment with nasal
douching, or monotherapy
○ Choice of concomitant treatment of comorbid allergy, asthma
or COPD
Also in CRS patients, education is a crucial step in the process of
patient participation.
F IGURE 4 Graded implementation of
precision medicine in chronic rhinosinusitis
(adapted from Hellings et al.11). CRSwNP,
chronic rhinosinusitis with nasal polyps;
CRSsNP:,chronic rhinosinusitis without
nasal polyps
F IGURE 3 Multisectoral care pathway
for allergic rhinitis (from Bousquet et al.35).
OTC, over-the-counter
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After having elaborated a treatment strategy with the CRS
patient, it is recommended to evaluate the degree of symptom con-
trol after a time interval of four weeks for patients with severe dis-
ease and three months for patients with mild-moderate disease.
Symptom control in CRS can be evaluated preferably by the appli-
cation of the EPOS criteria for control. It is estimated that up to 50% of
patients with CRS still remain symptomatic, with partially controlled or
uncontrolled CRS. The latter population is seen at specialist level, for
fine-tuning the diagnosis and designing an optimal therapeutic plan.
3.2 | Second-level management of CRS
Following the initiation of first-line treatment, uncontrolled CRS
patients are invited for evaluation of the achieved level of symptom
control and fine-tuning of the treatment strategy. Besides taking
into account the achieved level of control by first-line treatment, a
treatment strategy is elaborated according to the nasal endoscopic
findings, the needs and expectations of the patient, the experienced
efficacy and/or adverse events of the medication used, the avail-
ability of medication and the long-term goal of maintaining or
achieving disease control and/or secondary or tertiary prevention
of disease.
Therefore, the following key principles of PM can be imple-
mented during the follow-up consultation for CRS (Figure 5):
• Prediction of success of any step-down or step-up approach, with
information of the patient on the expected benefits and risks of
the chosen approach
• Participation of the patient in the therapeutic plan, with clear expla-
nation of the different treatment options for CRSwNP and CRSsNP,
including (long term) oral antibiotics and oral corticosteroids
• Prevention of disease progression with clear statements on the dif-
ferent approaches for suppression of inflammation vs prevention
of disease progression.
○ Secondary prevention in CRS aims to prevent the onset of
asthma in those CRS patients who have not developed asthma
symptoms or signs yet. Evidence-based therapeutic interventions
for the secondary prevention of asthma fall into two categories:
 Endoscopic sinus surgery (ESS): Recent evidence suggests
that ESS may be associated with a reduced likelihood of
developing asthma.46,47
 Control of exposure to environmental allergens and cigar-
ette smoke is considered important in preventing the dis-
ease progression. Retrospective data have shown the
impact of occupational exposure to low molecular weight
irritants on the success of ESS.48,49
○ Tertiary prevention aims to prevent irreversible damage to
the inflamed organ, maximizing the remaining capabilities and
functions of the organ. At this moment, tertiary prevention in
CRS has not been studied.
3.3 | Third-level management of CRS
Following second-line treatment, uncontrolled patients are evaluated
for advices regarding long-term therapeutic strategy, including the
position of ESS.29 At this stage, the majority of CRS patients with
uncontrolled disease are seeking specialist advice. Specialists are
supposed to fine-tune and reconsider the diagnosis in case of uncon-
trolled disease despite recommended treatment. At specialist level, a
treatment plan should ideally be proposed according to the needs of
the patient, the previously achieved level of control, the availability
of medication and the long-term goal.
All four key principles of PM should be implemented during the
follow-up consultation for CRS at specialist level (Figure 5):
• Prediction of success of medical versus surgical treatment, with
information of CRS patients on the expected benefits of each
F IGURE 5 Precision medicine
implementation in chronic rhinosinusitis.
ESS, endoscopic sinus surgery; Qol, quality
of life
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approach on the short and long term, and the risks or adverse
events of both approaches. ESS is successful for most disease
parameters in CRS, including asthma control, but persistent
inflammation and need for postoperative medical care need to
be discussed with the patient.50 Also the balance between
repetitive surgery, especially in patients with CRSwNP, and the
side-effect of intensified medical treatment should be dis-
cussed.51
• Participation of the patient in the therapeutic plan, with clear
information on the goals and practical implications of different
therapeutic strategies on the short and long term, including post-
operative care, importance of compliance to treatment regimes
and avoidance of irritants.
• Prevention of disease progression with clear approaches for sup-
pression of inflammation versus strategies for secondary preven-
tion of asthma.
• Personalized care with an endotype-driven treatment plan, including
biological treatment for CRSwNP, based on nasal inflammatory pat-
terns.52 Indeed, recent evidence highlights the benefit of biological
treatment in CRSwNP patients, with superiority over oral corticos-
teroid therapy.53-55 Easy-to-apply biomarkers are now needed to
identify those patients who might benefit from biological treatment.
4 | CONCLUSIONS
PM represents the way forward for improved care in patients with
chronic upper airway inflammation, and for prevention of asthma in
patients with rhinitis and rhinosinusitis. Despite the perception of
being associated with high cost of molecular analyses and biological
treatment, most principles of PM can already be implemented in
first- and secondary-level management without major costs. Given
the diverse nature of uncontrolled disease, even implementing three
of four principles of PM in routine care may lead to an increased
degree of patient satisfaction, control of disease and prevention of
asthma. AR patients may benefit from full control of disease with
prevention of asthma, by the combination of regular pharmacother-
apy and AIT. It is important to recognize that AR may be an optimal
model to identify molecular causes for variable treatment response:
AR is common, has a well-defined and accessible phenotype and
often known external triggers (allergens). The disease process can be
mimicked in vitro and in vivo to define novel biomarkers and drug
targets for PM. Despite the emerging evidence of biologicals being
the future of CRSwNP care, the long-term benefits still need to be
confirmed. In addition, future studies are needed to confirm the ben-
efit of the proposed care strategy for AR and CRS on socio-eco-
nomic level as well as on the level of patient satisfaction and control
of disease.
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